Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Naurex, Inc, an affiliate of Allergan plc115 enrolled

Overview

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

115

Conditions

Major Depressive Disorder

Interventions

GLYX-13DRUG

single IV dose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of major depressive disorder consistent with DSM-IV-TR * current episode greater than 8 weeks in duration * Hamilton Depression score \>/- 21 * less than 25% reduction in depression during current episode assessed by ATRQ Exclusion Criteria: * Axis diagnosis of other psychiatric disorders * Experiencing hallucinations, delusions, other psychotic symptomatology * ECT during current episode

Locations (1)

Mulitple

Evanston, Illinois, United States

Outcomes

Primary Outcomes

Change in depression score

Time frame: 14 days

Secondary Outcomes

Change in BPRS+

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.